Page 10 - Jan Mikkelsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Phase 3 PaTHway Trial - At Week 52, 95% of patients treated with TransCon PTH achieved independence from conventional therapy - TransCon PTH treatment improved mean patient-reported disease symptom and health-related quality of life scores, starting at the first scheduled follow up after randomization o

United statesNew jerseyBaden wübergRedwood cityJan mikkelsenBart clarkeAscendis pharmaExchange commissionEndocrine societyMayo clinicChief executiveAscendis pharma investorsPalo altoAscendi annual report

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Redwood cityUnited statesBaden wübergNew jerseyJan mikkelsenBart clarkeAscendis pharmaExchange commissionEndocrine societyMayo clinicChief executiveAscendis pharma investorsPalo altoAscendi annual report

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesBaden wübergRedwood cityJan mikkelsenAscendis pharmaMelinda bakerBart clarkeTim leeExchange commissionPatti bankEndocrine societyMayo clinicChief executiveAscendis pharma investorsPalo alto

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

07.06.2023 - COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate . Seite 1

Ascendis pharmaJan mikkelsenScott smithGoldman sachsChief executive officerVice presidentChief financial officerAnnual global healthcare conference

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

31.05.2023 - – TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon IL-2 β/γ administered every 3 weeks was . Seite 1

Ascendis pharmaJan mikkelsenStina singelWebcast of ascendi oncology programCompany oncologyHead of clinical developmentAscendi oncology program updateExecutive vice presidentClinical development